Evotec Shares Jump After Preliminary Nine-Month Results Beat Estimates
The German drug-discovery company's preliminary revenue and EBITDA both topped analyst forecasts, sending the stock higher.
Evotec's preliminary nine-month revenue and EBITDA (earnings before interest, tax, depreciation and amortization) both came in above Street estimates, lifting the shares.
BREAKING STORYBULLISH